Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Brain Behav Immun. 2021 Mar 15;95:168–177. doi: 10.1016/j.bbi.2021.03.014

Table 4.

Effect of Intervention and Covariates on Markers of Inflammation in Two-Level Mixed Models

TNF-± IL-10 IL-8 IL-6 CRP

Coef. (SE) β P Coef. (SE) β P Coef. (SE) β P Coef. (SE) β P Coef. (SE) β P
Intercept .50 (.04) 11.78 .000 .34 (.10) 3.60 .000 .96 (.07) 13.56 .000 .51 (.10) 4.89 .000 .70 (.17) 4.17 .000
Intervention −.01 (.02) −.69 .492 −.01 (.05) −.13 .894 .02 (.04) .54 .592 −.10 (.05) −1.93 .053 −.10 (.09) −1.10 .270
 CBSM vs. HP
Time
 6 mo. vs. Baseline .08 (.02) 5.04 .000 .16 (.03) 5.10 .000 .06 (.02) 2.88 .004 −.08 (.04) −1.85 .064 −.01 (.07) −.20 .840
 12 mo. vs. Baseline .01 (.02) .57 .568 .08 (.04) 2.01 .044 −.03 (.02) −1.03 .304 .09 (.05) 1.77 .077 .11 (.07) 1.47 .143
Intervention*Time
 CBSM
  6 mo. vs. Baseline .07 (.02) 4.37 .000 .12 (.03) 3.85 .000 .09 (.02) 4.09 .000 −.07 (.05) −1.55 .121 .00 (.07) .04 .972
  12 mo. vs. 6 mo. .07 (.02) 4.06 .000 .06 (.03) 1.91 .056 .06 (.02) 2.85 .004 .13 (.05) 2.70 .007 .05 (.07) .66 .511
 HP
  6 mo. vs. Baseline .08 (.02) 5.04 .000 .16 (.03) 5.10 .000 .06 (.02) 2.88 .004 −.08 (.04) −1.85 .064 −.01 (.07) −.20 .840
  12 mo. vs. 6 mo. .09 (.02) 5.24 .000 .08 (.03) 2.29 .022 .03 (.02) 1.53 .126 .17 (.05) 3.55 .000 .12 (.07) 1.66 .096
 CBSM vs. HP
  at Baseline −.01 (.02) −.69 .492 −.01 (.05) −.13 .894 .02 (.04) .54 .592 −.10 (.05) −1.93 .053 −.10 (.09) −1.10 .270
  at 6 mo. −.01 (.02) −.23 .816 .03 (.05) .59 .557 −.01 (.04) −1.20 .839 −.09 (.06) −1.54 .123 −.08 (.09) −.86 .391
  at 12 mo. −.03 (.03) −1.00 .316 .02 (.06) .27 .784 .02 (.04) .53 .596 .13 (.06) 2.04 .042 −.15 (.10) −1.56 .119
Age .00 (.00) 2.01 .044 .00 (.00) .98 .326 .00 (.00) 2.45 .014 .00 (.00) 1.81 .071 .00 (.00) −.84 .402
BMI .00 (.00) −1.35 .178 .00 (.00) .28 .776 .00 (.00) −.09 .932 .001 (.00) 1.56 .119 .02 (.01) 2.51 .012
Income (> 35k vs. <35k) .01 (.02) −.32 .747 −.03 (.06) −.55 .582 −.01 (.04) −.20 .838 −.09 (.06) −1.54 .123 −.04 (.09) −.38 .706
Race (White vs. Black/Other) .02 (.02) 1.10 .273 −.06 (.05) −1.24 .214 .05 (.04) 1.24 .216 −.02 (.05) −.46 .648 −.12 (.08) −1.36 .173
Metastasis (yes vs. no) −.03 (.02) −1.35 .178 .07 (.05) 1.43 .154 −.01 (.04) −.40 .692 .05 (.05) 1.07 .286 −.09 (.08) −1.04 .300
ADT (yes vs. no) .03 (.02) 1.68 .094 −.02 (.04) −.50 .616 −.01 (.03) −.32 .752 −.02 (.05) −.32 .750 −.06 (.08) −.68 .496
Radiation (yes vs. no) −.00 (.01) −.06 .951 .00 (.03) .10 .919 .03 (.02) 1.31 .192 .11 (.04) 2.74 .006 .06 (.06) .92 .355
Chemotherapy (yes vs. no) .09 (.03) 2.87 .004 −.02 (.07) −.27 .790 −.05 (.04) −1.22 .223 −.12 (.09) −1.39 .164 .09 (.13) .69 .493
Prostatectomy (yes vs. no) −.01 (.02) −.27 .789 .04 (.05) .65 .518 .05 (.04) 1.10 .273 −.06 (.06) −1.14 .254 .27 (.09) 2.91 .004
Years since diagnosis .00 (.00) 1.00 .317 .00 (.00) −.46 .649 .00 (.00) −1.44 .149 .00 (.00) −.30 .767 .00 (.01) −.16 .875
Charlson Comorbidities Index .01 (.01) 1.47 .140 .03 (.02) 1.64 .101 .01 (.01) .51 .611 .04 (.02) 2.57 .010 .04 (.03) 1.25 .213
Time from baseline to intervention completion .01 (.01) .89 .372 .00 (.02) .13 .899 .00 (.02) .25 .806 .01 (.02) .61 .539 −.02 (.04) −.50 .617

Note. Reference categories in binary variables are listed second. CBSM = Cognitive Behavioral Stress Management; HP = Health Promotion; SD = standard deviation; ADT androgen deprivation therapy; BMI = body mass index; Coef. = coefficient; SE = standard error.